Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned a Section Editors, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
Norman Letvin, MD, was a true pioneer in the development of nonhuman primate models for AIDS pathogenesis and vaccine research. He died in 2012 after a long battle with pancreatic cancer. In memory of his enormous contributions to this field, we dedicate the Animal Models section in this issue of Current Opinion in HIV and AIDS to him.
Louis J. Picker
Dr Louis J. Picker is currently the Associate Director of the Vaccine and Gene Therapy Institute, a Senior Scientist in the Pathobiology and Immunology Division of the Oregon National Primate Research Center, USA, and a Professor in the Oregon Health & Science University's Departments of Pathology and Molecular Microbiology and Immunology. Dr Picker was recruited to OHSU in 2000 from the Department of Pathology at the University of Texas Southwestern Medical Center at Dallas, USA, where he served as a Principal Investigator, Medical Director of the Clinical Immunology Laboratory, and Co-Director of the Division of Hematopathology and Immunology. He received his medical degree at the University of California, San Francisco, USA in 1982, did an internship, residency, and chief residency in anatomic and clinical pathology at the Beth Israel Hospital in Boston, Massachusetts, USA, from 1982 to 1986, and received advanced training in experimental pathology at Stanford University Medical Center in Palo Alto, California, USA from 1986 to 1989. Dr Picker is well known for his work elucidating human and nonhuman primate memory T cell biology, mechanisms of immune protection against persistent pathogens and the immunopathogenesis of AIDS, and the development of HIV/AIDS vaccines.
Dan H. Barouch
Dr Dan H. Barouch received his PhD in immunology from Oxford University, UK, and his MD from Harvard Medical School, USA. He is currently Professor of Medicine at Harvard Medical School and Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, USA. He is a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD), the NIH Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), and the Ragon Institute of MGH, MIT, and Harvard. His laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. His laboratory has explored a series of novel vaccine technologies, including adjuvanted DNA vaccines, poxvirus vectors, and alternative serotype adenovirus vectors in both preclinical and clinical studies. In particular, he has advanced a series of novel adenovirus vector-based HIV-1 vaccine candidates from concept and design to preclinical testing to phase 1 clinical trials that are currently underway in both the US and sub-Saharan Africa. Dr Barouch is board certified in Internal Medicine and Infectious Diseases, and he is committed to mentoring students, clinical fellows, research fellows, and junior faculty and to providing clinical care to patients with infectious diseases.
David A. Cooper
David A. Cooper AO FAA is Scientia Professor of Medicine and Director of the Kirby Institute at the University of New South Wales, Sydney, Australia. The Kirby Institute is funded by the Commonwealth Department of Health and Ageing to conduct research into blood-borne viruses including HIV and viral hepatitis in Australia with the ultimate aim of reducing the burden of disease for the affected communities.
The major responsibilities of the Kirby Institute are the epidemiology and surveillance of blood-borne viruses in Australia, including research aspects and the coordination and conduct of clinical trials of innovative therapies and vaccines for HIV and viral hepatitis, as well as an active clinical research program with particular emphasis on HIV infection, viral hepatitis and sexually-transmitted infections.
In addition to the Kirby Institute, Professor Cooper is a physician in the Immunology/HIV/Infectious Diseases Clinical Services Unit at St Vincent's Hospital, Sydney, Australia, one of the largest inpatient and outpatient services for the treatment of HIV disease in Australia. He is also Director of the St Vincent's Hospital Centre for Applied Medical Research. Professor Cooper is an author on over 750 published scientific papers and is on the editorial boards of several international journals.
Internationally, Professor Cooper is recognized as a leading HIV clinician and clinical investigator. He is a past President of the International AIDS Society. He is a Director of HIVNAT, a clinical research and trials collaboration based at the Thai Red Cross AIDS Research Centre at the Chulalongkorn University Hospital in Bangkok, Thailand. He is actively involved in strategic studies of antiretroviral therapy for HIV infection in the developed and developing world as well as studies of HIV vaccines and chemoprophylaxis.
Professor Giuseppe Pantaleo was born June 17, 1956 in Bari, Italy. In 1980, he received his degree in medicine with full marks and honors, and in 1983, he became board certified in clinical hematology.
His scientific career in the field of immunology began in 1983 working on the development of a limiting dilution cloning system which was critical for the subsequent studies aimed at the phenotypic and functional characterization of circulating T lymphocytes. From 1985 to 1987 he was amongst the pioneers in the delineation of the molecular and biochemical mechanisms involved in signal transduction in human T lymphocytes.
In 1989, Professor Pantaleo joined the Laboratory of Immunoregulation, NIAID, NIH. He was the first to demonstrate the defective clonogenic potential of CD8+ T lymphocytes and the selective defect of HIV-specific cytotoxic T lymphocytes. He then studied the relationship between immune response and viral reservoirs in different anatomic compartments. He demonstrated that lymphoid organs function as a major reservoir for HIV, and that active virus replication occurs in lymphoid organs throughout the course of HIV disease including the prolonged period of clinical latency. These findings have completely changed the clinical and therapeutic management of HIV infection. In the following years, Professor Pantaleo has continued to provide important contributions to the understanding the immunopathogenesis of HIV infection. Amongst these it is noteworthy to mention the delineation of the virologic and immunologic events associated with primary HIV infection, and the observation that the proportion of CD8+ T cells involved in antiviral immune response was substantially higher compared to what was previously estimated.
Since 1997 he has pioneered the field of immune-based intervention in HIV infection and he has been part of a European program for the development of a vaccine against HIV-AIDS. Since 2005, he is leading several HIV vaccine programs supported by the Bill and Melinda Gates Foundation.
Professor Pantaleo is author and co-author of more than 280 publications in international scientific journals; he is on the editorial boards of several international journals and serves as ad hoc reviewer for several international journals.
Professor Pantaleo is Professor of Medicine and Chief of the Division of Immunology and Allergy (IAL) and of the Laboratory of AIDS Immunopathogenesis at the Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland. Since 2007, he serves as Executive Director of the Swiss Vaccine Research Institute. Since 2009, he has been a member of the WHO Vaccine Program scientific committee and a member of the science committee of the Global HIV Vaccine Enterprise.